You are here: Home / Publications

Publications

 ARTICLES
  1. “Toripalimab, a therapeutic monoclonal anti-PD1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells”, Rajasekaran, N., Wang, X., Ravindranathan, S., Chin, D., Tseng, S.-Y., Klakamp, S. L., Widmann, K., Kapoor, V., Vexler, V., Keegan, P., Yao, S., LaVallee, T., and Khare, S. (2024) Cancer Immunol. Immun., 73, 60. https://doi.org/10.1007/s00262-024-03635-3.
  2. “Demonstration of physicochemical and functional similarity of biosimilar adalimumab-acvh to adalimumab”, Jiang, Y., Arora, T., Klakamp, S., Davis, J., Chandrasekher, Y., Young, G., Du, Y., Yu, B., Miller K.J (2023) Drugs in R&D, https://doi.org/10.1007/s40268-023-00437-3.
  3. “Miscalculating equilibrium constants for multivalent protein complexes: Site-binding concentration or protein molecular concentration?”, Klakamp, S.L. & Drake, A.W. (2021) J. Pharm. Sci. 110, 2585-2589.
  4. “Biacore surface matrix effects on the binding kinetics and affinity of an antigen/monoclonal antibody complex,” Drake, A.W., Tang, M., Papalia, G.A., Landes, G., Haak-Frendscho, M., and Klakamp. S.L. (2012) Anal. Biochem. 429, 58-69.
  5. “A strategic and systematic approach for the determination of biosensor regeneration conditions,” Drake, A.W. and Klakamp. S.L. (2011) J. Immunol. Methods 371, 165-169.
  6. “Surrogate approaches in development of monoclonal antibodies,” Gazit-Bornstein, G., Klakamp, S. L., Andrews, L., Boyle, W.J., and Tabrizi, M. (2009) Drug Discov. Today 14, 1159-1165.
  7. “A Global benchmark study using affinity-based biosensors,” Rich et al. (2009) Anal. Biochem. 386, 194-216.
  8. “Translational strategies for development of monoclonal antibodies from discovery to the clinic,” Tabrizi, M., Gazit-Bornstein, G., Klakamp, S. L., Drake, A., Knight, R., and Roskos, L. (2009) Drug Discov. Today 14, 298-305.
  9. “Application of analytical detection concepts to immunogenicity testing,” Klakamp, S.L., Coleman, D., Lu, H., Tabrizi, M., Funelas, C., Roskos, L.K. (2007) Anal. Chem. 79, 8176-8184.
  10. “Detection of high and low affinity antibodies against a human monoclonal antibody using various technology platforms,” Liang, M., Klakamp, S.L., Funelas, C., Lu, H., Lam, B., Herl, C., Umble, A., Drake, A.W., Pak, M., Ageyeva, N., Pasumarthi, R., Roskos, L.K. (2007) Assay Drug Dev. Techn., 5, 1-8.
  11. “A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants,” Drake, A.W. and Klakamp. S.L. (2007) J. Immunol. Methods 318, 157-162.
  12. “Screening antibody/antigen interactions in parallel using Biacore A100,” Safsten, P., Klakamp, S.L., Drake, A.W., Karlsson, R., and Myszka, D.G. (2006) Anal. Biochem. 353, 181-190.
  13. “Kinetic analysis of a high affinity antibody/antigen interaction performed by multiple Biacore users,” Katsamba, P.S. et al. (2006) Anal. Biochem. 352, 208-221.
  14. “Characterizing high affinity antigen/antibody complexes by kinetic- and equilibrium-based methods,” Drake, A.W., Myszka, D.G., and Klakamp, S.L. (2004) Anal. Biochem. 328, 35-43.
  15. “Kinetic screening of antibodies from crude hybridoma samples using Biacore,” Canziani, G.A., Klakamp, S.L., and Myszka, D.G. (2004) Anal. Biochem.325, 301-307.
  16. “The preparation, characterization and evaluation of cationic microparticles for DNA vaccine delivery,” Briones, M., Singh, M., Ugozzoli, M., Kazzaz, J., Klakamp, S., Ott, G., and O’Hagen, D. (2001) Pharm. Res., 18, 709-712.
  17. “Protective interactive non-condensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle,” Mumper, R.J., Wang, J., Klakamp, S.L., Nitta, H., Anwer, K., Tagliaferri, F., and Rolland, A.P. (1998) J. Cont. Rel. 52, 191-203.
  18. “Lanthanide ion luminescence as a probe of DNA structure. 1. guanine-containing oligomers and nucleotides,” Klakamp, S.L. and Horrocks, W. DeW., Jr. (1992) J. Inorg. Biochem. 46, 175-192.
  19. “Lanthanide ion luminescence as a probe of DNA structure. 2. non-guanine-containing oligomers and nucleotides,” Klakamp, S.L. and Horrocks, W. DeW., Jr. (1992) J. Inorg. Biochem. 46, 193-205.
  20. “The Europium(III)-induced conformational transitions of poly(dG-dC)•poly(dG-dC) and poly(dG-m5dC) •poly(dG-m5dC) as studied by Europium(III) luminescence, UV, and CD spectroscopy,” Klakamp, S.L. and Horrocks, W. DeW., Jr. (1990) Biopolymers 30, 33-43.
  21. “Laser-induced Europium(III) luminescence and NMR spectroscopic characterization of macrocyclic diaza crown ether complexes containing carboxylate ligating groups,” Holz, R.C., Klakamp, S.L., Chang, A.C., and Horrocks, W. DeW., Jr., (1990) Inorg. Chem. 29, 2651-2658.
PATENTS
  1. Confidential, unpublished patent application from Johnson & Johnson on a cell-based affinity method; Lacy, Powers & Klakamp as coinventors, submitted February 2024.
  2. “Anti-ILT4 compositions and methods,” Arora et al., Provisional United States Patent 63/324,544 and 63/374,250 submitted on March 28, 2022 and September 1, 2022.
  3. “Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,” Weber, R. et al., United States Patent 9,062,113 issued June 23, 2015.
  4. “Antibodies directed to tumor necrosis factor and uses thereof,” Babcock, J. et al., United States Patent 8,101,178 issued January 24, 2012.
  5. “Fully human monoclonal antibodies to IL-13,” Foltz, I. et al. (2006) United States Patent 7,994,302 issued August 9, 2011.
  6. “Antibodies against interleukin-1b,” Green, L. et al., United States Patent 7,964,193 issued June 21, 2011.
  7. “Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,” Weber, R. et al., United States Patent 7,736,644 issued June 15, 2010.
  8. “Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof,” Weber, R. et al., United States Patent 7,628,986 issued December 8, 2009.
  9. “Fully human monoclonal antibodies to IL-13,” Foltz, I. et al. (2006) United States Patent 7,585,500 issued September 8, 2009.
  10. “Antibodies against interleukin-1b,” Green, L. et al., United States Patent 7,566,772 issued July 28, 2009.
  11. “Antibodies directed to tumor necrosis factor and uses thereof,” Babcock, J. et al., United States Patent 7,285,269 issued October 23, 2007.
  12. “Antibodies directed to GPNMB and uses thereof,” Feng, Xiao et al., United States Patent 8,846,873 issued September 30, 2014.
  13. “Bioactive and/or targeted Starburst® dendrimer bioconjugates,” Tomalia, D.A. et al. United States Patent 5,714,166 issued February 3, 1998.
BOOKS AND BOOK CHAPTERS
  1. Development of Antibody-Based Therapeutics: Translational Considerations, Second Edition; Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., Eds.; Springer Nature Singapore Pte Ltd., 2018.
  2. Tabrizi, M.A. and Klakamp, S.L. “Considerations for Establishing Affinity Design Goals,” In Development of Antibody-Based Therapeutics: Translational Considerations, Second Edition, Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., Eds.; Springer Nature Singapore Pte Ltd., 2018.
  3. Frenzel, A., Roskos, L., Klakamp, S., Liang, M., Arends, R., Green, L., “Antibody Affinity,” In Handbook of Therapeutic Antibodies 2nd edition, Dubel, S. and Reichert, J. Eds.; Wiley-VCH: Weinheim, Germany, 2014; Vol. 1, Chapter 6.
  4. Development of Antibody-Based Therapeutics: Translational Considerations; Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., Eds.; Springer: New York, 2012.
  5. Funelas, C. and Klakamp, S.L. “Bioanalytical considerations for development of antibody-based therapeutics: pharmacokinetics and immunogenicity” In Development of Antibody-Based Therapeutics: Translational Considerations Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., Eds.; Springer: New York, 2012.
  6. Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., “Therapeutics: Translational Considerations,” In Development of Antibody-Based Therapeutics: Translational Considerations, Tabrizi, M.A., Bornstein, G.G., Klakamp, S.L., Eds.; Springer: New York, 2012; Chapter 1
  7. Drake, A.W., Myszka, D.G., and Klakamp, S.L. “Characterizing high affinity antigen/antibody complexes by kinetic- and equilibrium-based methods,” In Current Trends in Monoclonal Antibody Development and Manufacturing, Shire, S.J., Gombotz, W., Bechtold-Peters, K., and Andya, J. Eds.; Springer: New York, 2010; Chapter 11.
  8. Roskos, L., Klakamp, S., Liang, M., Arends, R., Green, L., “Molecular Engineering II: Antibody Affinity,” In Handbook of Therapeutic Antibodies, Dubel, S. Ed.; Wiley-VCH: Weinheim, Germany, 2007; Vol. 1, Chapter 7.
  9. Mumper, R.J. and Klakamp, S.L. “Polymeric gene delivery systems for in vivo gene therapy,” In Advanced Gene Delivery: From Concepts to Pharmaceutical Products; Rolland A.P., Ed.; Harwood Academic Publishers: Amsterdam, Netherlands, 1999; Chapter 7.
  10. Klakamp, S.L. and Barton, J.K. “DNA photofootprinting with Rh(phi)2bpy3+,” In Methods in Molecular Biology; Harwood, A. J., Ed.; Humana Press: Totowa, NJ, 1994; Vol. 31, Chapter 31.
INVITED SEMINARS
  1. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational Biotherapeutic Development Strategies, Part 2: Analytical and Clinical Considerations”, 15th Annual Protein Engineering Summit in Boston, MA, April 7, 2019
  2. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies”, 14th Annual Protein Engineering Summit in Boston, MA, April 29, 2018
  3. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies”, 13th Annual Protein Engineering Summit in Boston, MA, April 30, 2017
  4. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” 12th Annual Protein Engineering Summit in Boston, MA, April 24, 2016.
  5. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” 11th Annual Protein Engineering Summit in Boston, MA, May 3, 2015.
  6. “Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex”, Chairperson and Speaker in the “Challenges in Biophysical Analysis” section of the Analytical Stream at the 10th Annual Protein Engineering Summit in Boston, MA, May 8, 2014.
  7. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” 10th Annual Protein Engineering Summit in Boston, MA, May 4, 2014.
  8. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” Ninth Annual Protein Engineering Summit in Boston, MA, April 28, 2013.
  9. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” Eighth Annual Protein Engineering Summit in Boston, MA, April 29, 2012.
  10. “How do we measure the binding kinetics and affinities of antigen/monoclonal complexes?” instructor for a pre-conference short course on “Translational considerations for development of monoclonal antibodies: Focus on early discovery part 1” Seventh Annual Protein Engineering Summit in Boston, MA, May 8-13, 2011.
  11. “Biophysical Characterization of Therapeutic MAbs,” instructor for a pre-conference short course on “Essential Considerations for Development of Antibody-based Therapeutics from Discovery to the Clinic,” Sixth Annual Protein Engineering Summit in Boston, MA, May 17-21, 2010.
  12. “How do we measure affinity and the challenges,” instructor for a pre-conference short course on “Translational Strategies for Development of Monoclonal Antibodies from Discovery to the Clinic,” Fifth Annual Protein Engineering Summit in Boston, MA, April 6-10, 2009.
  13. “How do we measure affinity,” instructor for a pre-conference short course on “Translational Strategies for Development of Monoclonal Antibodies from Discovery to the Clinic,” 16th International Molecular Medicine Tri Conference in San Francisco, February 25-27, 2008.
  14. “How do we measure affinity and the challenges,” instructor for a pre-conference short course on “Development of Therapeutic Monoclonal Antibodies,” Fourth Annual Protein Engineering Summit in Boston, MA, April 28-May 2, 2008.
  15. “Managing false positive and false negative error rates and detection capabilities of immunogenicity testing,” at the University of Wisconsin Eighth Annual Land O’Lakes Bioanalytical Conference in Merrimac,WI, July 9-13, 2007.
  16. Panelist for the “Configuring informative immunogenicity assays for the development of biotherapeutics and vaccines,” roundtable at the DIPIA (Developments in Protein Interaction Analysis) conference in Phoenix, AZ, May 6-9, 2007.
  17. “Biacore uses in clinical immunological screening,” at the Biosensor Tools Workshop, Level II in Salt Lake City, UT, February 22-23, 2007.
  18. “Managing false positive and false negative error rates and detection capabilities in immunogenicity testing,” at the Immunogenicity for Biologics 2007 conference in Prague, Czech Republic, February 7-8, 2007.
  19. “Managing false positive and false negative error rates and detection capability in immunogenicity testing,” speaker at the Monoclonal Antibodies in Therapeutics conference in London, UK, September 11-13, 2006.
  20. “How long must I wait,” speaker for the workshop Current Trends in Monoclonal Antibody Development and Manufacturing at the AAPS National Biotechnology Conference, June 22-23, 2006.
  21. Panelist for the “The importance of high resolution kinetic data in the drug discovery and development process,” roundtable at the DIPIA (Developments in Protein Interaction Analysis) conference in Philadelphia, PA, August 28-31, 2005.
  22. “How long must I wait,” speaker at the First KinExA Symposium, October 19-20, 2004, Boise, ID.
  23. “How long must I wait,” speaker at the Gordon Research Conference on Reversible Associations in Structural and Molecular Biology, January 25-30, 2004, Ventura, CA.
  24. “Surface plasmon resonance: A new interdisciplinary tool for the study of biomolecular interactions,” inaugural speaker at an interdisciplinary seminar series at Houghton College, Houghton, NY, October 3, 2002.
  25. “Eu(III) luminescence spectroscopy as a probe of DNA structure,” speaker for a chemistry seminar at Houghton College, Houghton NY, January 20, 1990.